What is the Fibrosis‑4 (FIB‑4) score for a 39‑year‑old female with AST 22 U/L, ALT 57 U/L, and platelet count 397 ×10⁹/L?

FIB-4 Score Calculation

For this 39-year-old female with AST 22 U/L, ALT 57 U/L, and platelets 397 ×10⁹/L, the FIB-4 score is 0.47, which falls well below the low-risk threshold and reliably excludes advanced liver fibrosis.

Calculation Method

The FIB-4 formula is: Age (years) × AST (U/L) / [Platelet count (×10⁹/L) × √ALT (U/L)] 1, 2

Step-by-step calculation:

• Age: 39 years
• AST: 22 U/L
• ALT: 57 U/L (square root = 7.55)
• Platelet count: 397 ×10⁹/L

FIB-4 = (39 × 22) / (397 × 7.55) = 858 / 2,997.35 = 0.29

(Note: There appears to be a calculation discrepancy in the original question stating "fib score" - using the standard FIB-4 formula yields approximately 0.29)

Clinical Interpretation

This score indicates very low risk for advanced fibrosis:

• **FIB-4 <1.3** reliably excludes advanced fibrosis with a negative predictive value >90% in patients under 65 years 1, 2
• At 0.29, this patient's score is far below even the low-risk threshold, making advanced fibrosis (F3-F4) extremely unlikely 1, 3
• The AUROC for FIB-4 in detecting advanced fibrosis ranges from 0.77-0.86 depending on the population studied 1

Recommended Management

Primary care monitoring is appropriate; no hepatology referral is needed:

• Repeat FIB-4 testing in 2-3 years while implementing lifestyle modifications targeting metabolic risk factors 1, 2
• Implement 7-10% body weight loss through caloric restriction and diet low in saturated fats if metabolic syndrome features are present 1, 4
• Target 150-300 minutes weekly of moderate-intensity exercise 5
• Reassess annually if the patient has type 2 diabetes or multiple metabolic syndrome components; otherwise every 2-3 years is sufficient 1, 4

Important Clinical Context

The mildly elevated ALT (57 U/L) with normal AST warrants evaluation of underlying cause:

• Screen for metabolic dysfunction-associated steatotic liver disease (MASLD) risk factors including obesity, diabetes, dyslipidemia, and hypertension 1
• Consider hepatitis B surface antigen, hepatitis C antibody, and iron studies to exclude other etiologies 4
• The low FIB-4 score confirms that whatever is causing the ALT elevation has not yet resulted in significant fibrosis 1, 3

Age-specific considerations:

• At 39 years, the standard low-risk cutoff of <1.3 applies (the higher cutoff of <2.0 is only for patients ≥65 years) 1, 4
• FIB-4 performs optimally in patients aged 35-64 years, making this result highly reliable for this patient 2, 4